{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:07:31Z","timestamp":1793210851553,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite current guidelines recommending against intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients with direct oral anticoagulants (DOAC) within prior 48\u00a0h, latest real-world data indicate no increased bleeding risk. However, these observations are based mainly on alteplase (rt-PA), whereas data for tenecteplase (TNK) are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively compared data from our stroke registry of AIS-patients with DOAC (intake within the last 48\u00a0h), who received IVT either with rt-PA or TNK without prior antagonization. The primary outcome was the rate of symptomatic intracranial hemorrhage (sICH) per SITS-Most criteria. Secondary outcomes included the rate of any ICH or major bleeding, rate of mortality, neurological and functional outcome at discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      82 AIS-patients were included, with 42 patients receiving TNK und 40 patients receiving rt-PA. Median age was 83 y for TNK patients and 82 y for rt-PA patients. Median NIHSS score at admission for TNK was 9 points for both groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.61). Median drug-specific DOAC plasma level was 49 ng\/mL for TNK\n                      <jats:italic>versus<\/jats:italic>\n                      24 ng\/mL for rt-PA (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). We found no statistically significant increased risk for neither sICH (TNK 2.4% vs. rt-PA 2.5%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091), nor for other safety outcomes for TNK-treated patients compared with rt-PA. The rate of excellent functional outcome (TNK 61.9% vs. rt-PA 52.5%) was similar among both groups. High drug-specific DOAC plasma levels were not related to an increased rate of hemorrhagic complications in our cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We report no increased rate of (s)ICH for TNK based IVT compared with rt-PA in AIS-patients with DOAC, indicating a similar safety profile. Moderate to high drug-specific DOAC levels were no surrogates for hemorrhagic complications, supporting the implementation of specific Standard Operating Procedures for IVT in DOAC-treated patients. Contrary to previous studies, we did not observe an increased rate of early recanalization of LVO in TNK-treated patients in this small single-center cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>n\/A.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-025-00450-8","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:25:56Z","timestamp":1763141156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety of tenecteplase versus alteplase for intravenous thrombolysis in acute ischemic stroke patients with direct oral anticoagulation: experience from a German stroke center"],"prefix":"10.1186","volume":"7","author":[{"given":"Lena","family":"Mers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bogdanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sekita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kallmuenzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6020-8290","authenticated-orcid":false,"given":"Stefan T.","family":"Gerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"6","key":"450_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00115-023-01500-9","volume":"94","author":"P Ringleb","year":"2023","unstructured":"Ringleb, P., Bauer, G., & Purrucker, J. (2023). Intraven\u00f6se thrombolyse des isch\u00e4mischen Schlaganfalls \u2013 aktueller stand. Der Nervenarzt, 94(6), 551\u2013563.","journal-title":"Der Nervenarzt"},{"issue":"3","key":"450_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jamaneurol.2022.4782","volume":"80","author":"TR Meinel","year":"2023","unstructured":"Meinel, T. R., et al. (2023). Intravenous thrombolysis in patients with ischemic stroke and recent ingestion of direct oral anticoagulants. JAMA Neurol, 80(3), 233\u2013243.","journal-title":"JAMA Neurol"},{"issue":"5","key":"450_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/jnnp-2020-325456","volume":"92","author":"DJ Seiffge","year":"2021","unstructured":"Seiffge, D. J., et al. (2021). Recanalisation therapies for acute ischaemic stroke in patients on direct oral anticoagulants. Journal of Neurology, Neurosurgery and Psychiatry, 92(5), 534\u2013541.","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"450_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00415-024-12832-0","volume":"272","author":"ES Kristoffersen","year":"2024","unstructured":"Kristoffersen, E. S., Seiffge, D. J., & Meinel, T. R. (2024). Intravenous thrombolysis and mechanical thrombectomy in acute stroke patients on direct oral anticoagulants. Journal of Neurology, 272(1), 82.","journal-title":"Journal of Neurology"},{"issue":"9958","key":"450_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","volume":"384","author":"J Emberson","year":"2014","unstructured":"Emberson, J., et al. (2014). Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with Alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials. Lancet, 384(9958), 1929\u20131935.","journal-title":"Lancet"},{"issue":"9","key":"450_CR6","doi-asserted-by":"publisher","first-page":"e209961","DOI":"10.1212\/WNL.0000000000209961","volume":"103","author":"A Ranta","year":"2024","unstructured":"Ranta, A. (2024). The time has come. The time is now. IV Alteplase, will you please go now? Neurology, 103(9), e209961.","journal-title":"Neurology"},{"issue":"7","key":"450_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaneurol.2023.1449","volume":"80","author":"SJ Warach","year":"2023","unstructured":"Warach, S. J., et al. (2023). Symptomatic intracranial hemorrhage with tenecteplase vs Alteplase in patients with acute ischemic stroke: The comparative effectiveness of routine tenecteplase vs Alteplase in acute ischemic stroke (CERTAIN) collaboration. JAMA Neurol, 80(7), 732\u2013738.","journal-title":"JAMA Neurol"},{"issue":"10","key":"450_CR8","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.1161\/STROKEAHA.121.035931","volume":"52","author":"K Mahawish","year":"2021","unstructured":"Mahawish, K., et al. (2021). Switching to tenecteplase for stroke thrombolysis: Real-world experience and outcomes in a regional stroke network. Stroke, 52(10), e590\u2013e593.","journal-title":"Stroke"},{"issue":"9","key":"450_CR9","doi-asserted-by":"publisher","first-page":"e031692","DOI":"10.1161\/JAHA.123.031692","volume":"13","author":"L Wang","year":"2024","unstructured":"Wang, L., et al. (2024). Comprehensive review of tenecteplase for thrombolysis in acute ischemic stroke. J Am Heart Assoc, 13(9), e031692.","journal-title":"J Am Heart Assoc"},{"issue":"10347","key":"450_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","volume":"400","author":"BK Menon","year":"2022","unstructured":"Menon, B. K., et al. (2022). Intravenous tenecteplase compared with Alteplase for acute ischaemic stroke in Canada (AcT): A pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. The Lancet, 400(10347), 161\u2013169.","journal-title":"The Lancet"},{"issue":"11","key":"450_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1474-4422(24)00377-6","volume":"23","author":"KW Muir","year":"2024","unstructured":"Muir, K. W., et al. (2024). Tenecteplase versus Alteplase for acute stroke within 4\u00b75\u00a0h of onset (ATTEST-2): A randomised, parallel group, open-label trial. Lancet Neurology, 23(11), 1087\u20131096.","journal-title":"Lancet Neurology"},{"issue":"10377","key":"450_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","volume":"401","author":"Y Wang","year":"2023","unstructured":"Wang, Y., et al. (2023). Tenecteplase versus Alteplase in acute ischaemic cerebrovascular events (TRACE-2): A phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet, 401(10377), 645\u2013654.","journal-title":"Lancet"},{"issue":"3","key":"450_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/STROKEAHA.120.030859","volume":"52","author":"CS Zhong","year":"2021","unstructured":"Zhong, C. S., et al. (2021). Routine use of tenecteplase for thrombolysis in acute ischemic stroke. Stroke, 52(3), 1087\u20131090.","journal-title":"Stroke"},{"issue":"5","key":"450_CR14","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/STROKEAHA.122.042335","volume":"54","author":"D Rose","year":"2023","unstructured":"Rose, D., et al. (2023). Complications of intravenous tenecteplase versus Alteplase for the treatment of acute ischemic stroke: A systematic review and meta-analysis. Stroke, 54(5), 1192\u20131204.","journal-title":"Stroke"},{"issue":"6","key":"450_CR15","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.annemergmed.2023.03.022","volume":"82","author":"LR Murphy","year":"2023","unstructured":"Murphy, L. R., et al. (2023). Tenecteplase versus Alteplase for acute stroke: Mortality and bleeding complications. Annals of Emergency Medicine, 82(6), 720\u2013728.","journal-title":"Annals of Emergency Medicine"},{"issue":"3","key":"450_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s13311-023-01391-3","volume":"20","author":"SE Miller","year":"2023","unstructured":"Miller, S. E., & Warach, S. J. (2023). Evolving thrombolytics: From Alteplase to tenecteplase. Neurotherapeutics, 20(3), 664\u2013678.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"450_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/23969873221150022","volume":"8","author":"S Alamowitch","year":"2023","unstructured":"Alamowitch, S., et al. (2023). European stroke organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J, 8(1), 8\u201354.","journal-title":"Eur Stroke J"},{"issue":"8","key":"450_CR18","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1177\/0271678X241237427","volume":"44","author":"C Correa-Paz","year":"2024","unstructured":"Correa-Paz, C., et al. (2024). Pharmacological preclinical comparison of tenecteplase and Alteplase for the treatment of acute stroke. Journal of Cerebral Blood Flow and Metabolism, 44(8), 1306\u20131318.","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"450_CR19","doi-asserted-by":"crossref","unstructured":"Purrucker, J. C., et al. (2024). Thrombolysis for ischaemic stroke despite direct oral anticoagulation. Stroke Vasc Neurol.","DOI":"10.1136\/svn-2023-002727"},{"key":"450_CR20","doi-asserted-by":"publisher","first-page":"108523","DOI":"10.1016\/j.clineuro.2024.108523","volume":"246","author":"K Alam","year":"2024","unstructured":"Alam, K., et al. (2024). Assessing mortality and safety of IV thrombolysis in ischemic stroke patients on direct oral anticoagulants (DOACs): A systematic review and meta-analysis. Clinical Neurology and Neurosurgery, 246, 108523.","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"1","key":"450_CR21","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/2396987321989865","volume":"6","author":"E Berge","year":"2021","unstructured":"Berge, E., et al. (2021). European stroke organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J, 6(1), I\u2013lxii.","journal-title":"Eur Stroke J"},{"issue":"12","key":"450_CR22","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"WJ Powers","year":"2019","unstructured":"Powers, W. J., et al. (2019). Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American heart association\/American stroke association. Stroke, 50(12), e344\u2013e418.","journal-title":"Stroke"},{"key":"450_CR23","doi-asserted-by":"crossref","unstructured":"B\u00fccke, P. (2024). Intravenous thrombolysis in patients with recent intake of direct oral anticoagulants: A target trial analysis after the liberalization of institutional guidelines. Eur Stroke J, p. 23969873241252751.","DOI":"10.1177\/23969873241252751"},{"issue":"1","key":"450_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ane.13622","volume":"146","author":"E Bergh","year":"2022","unstructured":"Bergh, E., et al. (2022). Reasons and predictors of non-thrombolysis in patients with acute ischemic stroke admitted within 4.5 h. Acta Neurologica Scandinavica, 146(1), 61\u201369.","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1","key":"450_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jamainternmed.2023.6160","volume":"184","author":"TY Tsai","year":"2024","unstructured":"Tsai, T. Y., et al. (2024). Risk of bleeding following non-vitamin K antagonist oral anticoagulant use in patients with acute ischemic stroke treated with Alteplase. JAMA Intern Med, 184(1), 37\u201345.","journal-title":"JAMA Intern Med"},{"issue":"24","key":"450_CR26","doi-asserted-by":"publisher","first-page":"e031669","DOI":"10.1161\/JAHA.123.031669","volume":"12","author":"M Ghannam","year":"2023","unstructured":"Ghannam, M., et al. (2023). Intravenous thrombolysis for acute ischemic stroke in patients with recent direct oral anticoagulant use: A systematic review and meta-analysis. J Am Heart Assoc, 12(24), e031669.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"450_CR27","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jama.2022.0948","volume":"327","author":"W Kam","year":"2022","unstructured":"Kam, W., et al. (2022). Association of recent use of non\u2013vitamin K antagonist oral anticoagulants with intracranial hemorrhage among patients with acute ischemic stroke treated with Alteplase. Journal of the American Medical Association, 327(8), 760\u2013771.","journal-title":"Journal of the American Medical Association"},{"key":"450_CR28","doi-asserted-by":"publisher","first-page":"175628642412762","DOI":"10.1177\/17562864241276206","volume":"17","author":"A Kleeberg","year":"2024","unstructured":"Kleeberg, A., et al. (2024). Hemorrhagic complications after stroke treatment with intravenous thrombolysis despite use of direct oral Anticoagulants: An observational study. Therapeutic Advances in Neurological Disorders, 17, 17562864241276206.","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"2","key":"450_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/STROKEAHA.119.026426","volume":"51","author":"S Shahjouei","year":"2020","unstructured":"Shahjouei, S., et al. (2020). Safety of intravenous thrombolysis among patients taking direct oral anticoagulants: A systematic review and meta-analysis. Stroke, 51(2), 533\u2013541.","journal-title":"Stroke"},{"issue":"5","key":"450_CR30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ana.27058","volume":"96","author":"S Monjazeb","year":"2024","unstructured":"Monjazeb, S., Chang, H. V., & Lyden, P. D. (2024). Before, during, and after: An argument for safety and improved outcome of thrombolysis in acute ischemic stroke with direct oral anticoagulant treatment. Annals of Neurology, 96(5), 871\u2013886.","journal-title":"Annals of Neurology"},{"issue":"1","key":"450_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s42466-025-00388-x","volume":"7","author":"A Sekita","year":"2025","unstructured":"Sekita, A., et al. (2025). Switch to tenecteplase for intravenous thrombolysis in stroke patients: Experience from a German high-volume stroke center. Neurological Research and Practice, 7(1), 28.","journal-title":"Neurological Research and Practice"},{"issue":"9558","key":"450_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","volume":"369","author":"N Wahlgren","year":"2007","unstructured":"Wahlgren, N., et al. (2007). Thrombolysis with Alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): An observational study. Lancet, 369(9558), 275\u2013282.","journal-title":"Lancet"},{"key":"450_CR33","doi-asserted-by":"crossref","unstructured":"Schulman, S. and C. Kearon. (2005). Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non\u2010surgical patients. Journal of Thrombosis and Haemostasis, 3(4), 692\u2013694.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"450_CR34","doi-asserted-by":"crossref","unstructured":"Matusevicius, M. (2025). Intravenous Thrombolysis in Patients Taking Direct Oral Anticoagulation Treatment Before Stroke Onset: Results from the Safe Implementations of Treatments in Stroke International Stroke Registry. Ann Neurol.","DOI":"10.1002\/ana.27256"},{"issue":"1","key":"450_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12883-023-03498-8","volume":"23","author":"AH Behnoush","year":"2023","unstructured":"Behnoush, A. H., et al. (2023). Meta-analysis of outcomes following intravenous thrombolysis in patients with ischemic stroke on direct oral anticoagulants. Bmc Neurology, 23(1), 440.","journal-title":"Bmc Neurology"},{"issue":"3","key":"450_CR36","first-page":"399","volume":"25","author":"P Koscumb","year":"2024","unstructured":"Koscumb, P., et al. (2024). Support for thrombolytic therapy for acute stroke patients on direct oral anticoagulants: Mortality and bleeding complications. West J Emerg Med, 25(3), 399\u2013406.","journal-title":"West J Emerg Med"},{"issue":"1","key":"450_CR37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1161\/STROKEAHA.120.030220","volume":"52","author":"AH Katsanos","year":"2021","unstructured":"Katsanos, A. H., et al. (2021). Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions: Systematic review and meta-analysis. Stroke, 52(1), 308\u2013312.","journal-title":"Stroke"},{"issue":"4","key":"450_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s11239-018-1721-3","volume":"46","author":"B Kheiri","year":"2018","unstructured":"Kheiri, B., et al. (2018). Tenecteplase versus Alteplase for management of acute ischemic stroke: A pairwise and network meta-analysis of randomized clinical trials. Journal of Thrombosis and Thrombolysis, 46(4), 440\u2013450.","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"1","key":"450_CR39","doi-asserted-by":"publisher","first-page":"102307","DOI":"10.1016\/j.rpth.2023.102307","volume":"8","author":"EK Amundsen","year":"2024","unstructured":"Amundsen, E. K., et al. (2024). Acute ischemic stroke and measurement of Apixaban and rivaroxaban: An observational cohort implementation study. Res Pract Thromb Haemost, 8(1), 102307.","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"450_CR40","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1055\/s-0041-1731777","volume":"05","author":"J Beyer-Westendorf","year":"2021","unstructured":"Beyer-Westendorf, J., Fay, M., & Amara, W. (2021). The importance of appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation. TH Open, 05(03), e353\u2013e362.","journal-title":"TH Open"},{"issue":"1","key":"450_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/svn-2023-002310","volume":"9","author":"Y Xiong","year":"2024","unstructured":"Xiong, Y., et al. (2024). Rationale and design of tenecteplase reperfusion therapy in acute ischaemic cerebrovascular events III (TRACE III): A randomised, phase III, open-label, controlled trial. Stroke Vasc Neurol, 9(1), 82\u201389.","journal-title":"Stroke Vasc Neurol"},{"issue":"3","key":"450_CR42","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/ana.26547","volume":"93","author":"V Yogendrakumar","year":"2023","unstructured":"Yogendrakumar, V., et al. (2023). Tenecteplase improves reperfusion across time in large vessel stroke. Annals of Neurology, 93(3), 489\u2013499.","journal-title":"Annals of Neurology"},{"issue":"7_Supplement_1","key":"450_CR43","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1212\/WNL.0000000000211050","volume":"104","author":"G Badger","year":"2025","unstructured":"Badger, G., et al. (2025). Early recanalization and distal thrombus migration in large vessel occlusion stroke undergoing bridging thrombolysis with Alteplase versus tenecteplase (S22.010). Neurology, 104(7_Supplement_1), 3502\u2013p.","journal-title":"Neurology"},{"issue":"4","key":"450_CR44","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/STROKEAHA.118.023877","volume":"50","author":"K Macha","year":"2019","unstructured":"Macha, K., et al. (2019). Cerebral ischemia in patients on direct oral anticoagulants. Stroke, 50(4), 873\u2013879.","journal-title":"Stroke"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00450-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:35:27Z","timestamp":1770705327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42466-025-00450-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00450-8","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the approval of the ethics committee. The ethics vote number 377_17 Bc was obtained for the project titled \u201cClinical follow-up of patients with acute stroke\u201d on 25 May 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}